PT - JOURNAL ARTICLE AU - Silvia Aldi AU - Ken-ichi Takano AU - Kengo Tomita AU - Kenichiro Koda AU - Noel Y.-K. Chan AU - Alice Marino AU - Mariselis Salazar-Rodriguez AU - Robin L. Thurmond AU - Roberto Levi TI - Histamine H<sub>4</sub>-Receptors Inhibit Mast Cell Renin Release in Ischemia/Reperfusion via Protein Kinase C<em>ε</em>-Dependent Aldehyde Dehydrogenase Type-2 Activation AID - 10.1124/jpet.114.214122 DP - 2014 Jun 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 508--517 VI - 349 IP - 3 4099 - http://jpet.aspetjournals.org/content/349/3/508.short 4100 - http://jpet.aspetjournals.org/content/349/3/508.full SO - J Pharmacol Exp Ther2014 Jun 01; 349 AB - Renin released by ischemia/reperfusion (I/R) from cardiac mast cells (MCs) activates a local renin-angiotensin system (RAS) causing arrhythmic dysfunction. Ischemic preconditioning (IPC) inhibits MC renin release and consequent activation of this local RAS. We postulated that MC histamine H4-receptors (H4Rs), being Gαi/o-coupled, might activate a protein kinase C isotype–ε (PKCε)–aldehyde dehydrogenase type-2 (ALDH2) cascade, ultimately eliminating MC-degranulating and renin-releasing effects of aldehydes formed in I/R and associated arrhythmias. We tested this hypothesis in ex vivo hearts, human mastocytoma cells, and bone marrow–derived MCs from wild-type and H4R knockout mice. We found that activation of MC H4Rs mimics the cardioprotective anti-RAS effects of IPC and that protection depends on the sequential activation of PKCε and ALDH2 in MCs, reducing aldehyde-induced MC degranulation and renin release and alleviating reperfusion arrhythmias. These cardioprotective effects are mimicked by selective H4R agonists and disappear when H4Rs are pharmacologically blocked or genetically deleted. Our results uncover a novel cardioprotective pathway in I/R, whereby activation of H4Rs on the MC membrane, possibly by MC-derived histamine, leads sequentially to PKCε and ALDH2 activation, reduction of toxic aldehyde-induced MC renin release, prevention of RAS activation, reduction of norepinephrine release, and ultimately to alleviation of reperfusion arrhythmias. This newly discovered protective pathway suggests that MC H4Rs may represent a new pharmacologic and therapeutic target for the direct alleviation of RAS-induced cardiac dysfunctions, including ischemic heart disease and congestive heart failure.